The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
A large interindividual variation in the activity of cytochrome P450 1A2 (CYP1A2) raises concern about therapeutic failure or toxicity when medical professionals prescribe drugs extensively metabolized by CYP1A2. To date, a number of studies have assessed the association between genetic polymorphisms and CYP1A2 activity; however, there are controversies as to the functional importance of CYP1A2 polymorphisms on the metabolism of CYP1A2 substrates. This systematic review and meta-analysis assessed the effects of genetic polymorphisms on CYP1A2 activity, as measured by caffeine metabolism, in a total of 3570 individual subjects. Higher enzyme activity was observed among those who were homozygous or heterozygous for the -163C>A polymorphism (rs762551), when compared to the wild-type individuals (SMD = 0.40, 95%CI = 0.12-0.68, p = 0.005; SMD = 0.32, 95%CI = 0.11-0.54, p = 0.003, respectively) and this was more pronounced among smokers (SMD = 0.92, 95%CI = 0.27-1.57, p = 0.005; SMD = 0.56, 95%CI = 0.22-0.90, p = 0.001, respectively). For other CYP1A2 polymorphisms, altered caffeine metabolic ratios were not seen. Our results indicate the functional importance of -163C>A polymorphism on CYP1A2 inducibility in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent meta-analysis revealed that hetero- and homozygosity for a single-nucleotide polymorphism (C → A) within the gene encoding the caffeine-metabolizing protein CYP1A2 resulted in a greater ratio of paraxanthine to caffeine, an effect accentuated by tobacco smoking.87”
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“Cytochrome P450 family 1 subfamily A member 2 (CYP1A2) is a major drug-metabolizing enzyme in the human liver, accounting for ~13–15% of the total cytochrome P450 enzyme [1].”
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Meta‐analysis of skewed data: Combining results reported on log‐transformed or raw scales
Higgins, J. P. T., White, I. R., & Anzures‐Cabrera, J. (2008) · Statistics in Medicine · doi:10.1002/sim.3427 · Cited by 481
Streetman, D. S., Bertino, J. S., & Nafziger, A. N. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00001 · Cited by 425
Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer‐Jensen, M., & Kadlubar, F. F. (1994) · PubMed · Cited by 388
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Cited by
Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis
Elfaki, I., Mir, R., Almutairi, F. M., & Abuduhier, F. M. (2018) · PubMed · doi:10.22034/apjcp.2018.19.8.2057 · Cited by 218
Sport Nutrigenomics: Personalized Nutrition for Athletic Performance
Guest, N. S., Horne, J., Vanderhout, S. M., & El-Sohemy, A. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00008 · Cited by 174
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes
Kwon, Y., Shin, S., & Chun, Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01306-w · Cited by 117
Grzegorzewski, J., Bartsch, F., Köller, A., & König, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752826 · Cited by 108
The Role of Genetics in Moderating the Inter-Individual Differences in the Ergogenicity of Caffeine
Southward, K., Rutherfurd-Markwick, K., Badenhorst, C., & Ali, A. (2018) · Nutrients · doi:10.3390/nu10101352 · Cited by 81
Metadata
- Authors
- Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S.
- Affiliations
- Chiang Mai University (TH)
- Corresponding author
- Koonrungsesomboon, Nut
- Venue
- The Pharmacogenomics Journal
- Published
- 2017-12-27
- Volume
- 18
- Issue
- 6
- Pages
- 760-768
- ISSN
- 1470-269X (ISSN-L)
- 1473-1150
- OpenAlex
- W2778169311
- Cited by
- 100
- References
- 54
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 11 · 2023: 12 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 8 · 2018: 4
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- The Pharmacogenomics Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Keywords
- CYP1A2, genetic polymorphism, caffeine metabolism, rs762551, enzyme activity, smokers, drug metabolism, interindividual variability
- MeSH terms
- Pharmacogenomic Variants, Smokers, Adolescent, Adult, Aged, Aged, 80 and over, Caffeine, Female, Heterozygote, Homozygote, Humans, Male, Middle Aged, Pharmacogenetics, Phenotype, Polymorphism, Genetic, Risk Factors, Smoking, Substrate Specificity, Cytochrome P-450 CYP1A2, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41397-017-0011-3
- The paper
- Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018). The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. The Pharmacogenomics Journal. https://doi.org/10.1038/s41397-017-0011-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.